PureTech Health (PRTC) noted that its founded entity, Vor Bio (VOR) and RemeGen announced entry into an exclusive license agreement granting Vor Bio global rights to develop and commercialize telitacicept, a novel dual-target fusion protein approved in China for generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis. Under the terms of the agreement, Vor Bio will pay RemeGen an initial payment of $125M consisting of an upfront payment of $45M as well as $80M of warrants to purchase common stock with an exercise price of $0.0001 per share. The agreement also provides for potential regulatory and commercial milestones exceeding $4B, in addition to tiered royalties.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTC:
- Positive Outlook on PureTech Health Driven by Promising LYT-100 Clinical Trial Results and Strategic Developments
- PureTech Health presents deupirfenidone data at ATS conference
- PureTech Health publishes new research in BMC Pulmonary Medicine
- Optimistic Buy Rating on PureTech Health Driven by Promising LYT-100 Developments and Strategic Growth Plans
- PureTech Health Reports Strong 2024 Financial Results